Sponsors (2)
The bill increases drug supply‑chain transparency and can improve safety, counterfeit detection, and customs efficiency, but imposes compliance and administrative costs, creates importer/legal uncertainty, and raises security and provenance‑accuracy risks that could raise prices or complicate enforcement.
Patients (including those with chronic conditions) and clinicians can more easily identify original drug manufacturers and API sources, improving traceability for recalls and contamination investigations and speeding safety responses.
Consumers can access supply‑chain provenance via label QR/links or a searchable portal, helping verify product authenticity and reduce counterfeit risk.
Importers and customs-related operations benefit from simpler compliance (FDA labeling can substitute for separate country‑of‑origin marks) and fewer marking disputes, potentially speeding customs processing and lowering administrative friction.
Manufacturers, packers, and distributors must incur compliance costs to update labels, maintain portals, and provide paper copies on request, which could raise drug prices that affect many patients.
Importers may face legal and implementation uncertainty about which products qualify as 'finished drug products' under the exemption, creating compliance costs, risk of shipment delays, and potential penalties if FDA standards are interpreted narrowly or change.
Listing facility names and locations on labeling could expose suppliers' security vulnerabilities or proprietary sourcing strategies, raising privacy and business‑confidentiality concerns for supply‑chain entities.
Based on analysis of 3 sections of legislative text.
Requires finished drugs and APIs to carry label or linked portal info naming original manufacturers and supply‑chain entities, and exempts such labeled drugs from certain import marking rules.
Requires finished drug products and active pharmaceutical ingredients (APIs) to carry labels or linked electronic information that identify the original manufacturers and key supply‑chain entities by name, business location, and a unique facility identifier (or via a barcode/QR/link to a searchable portal). Manufacturers, packers, and distributors must provide that information electronically and supply a paper/package‑insert copy on request. The law also exempts finished drugs marked this way from certain country‑of‑origin import marking rules. The agency must issue implementation rules, which cannot take effect sooner than one year after the final rule is published and will apply to drugs manufactured on or after that effective date.
Introduced April 14, 2026 by Rich McCormick · Last progress April 14, 2026